• Open Access IconOpen Access
  • Cite Icon55
  • https://doi.org/10.3390/vaccines7030077Copy DOI Icon

Nanobodies that Neutralize HIV

  • Jul 31, 2019
  • Vaccines
  • Robin A Weiss +1 more
Show More
  • Abstract
  • Highlights & Summary
  • PDF
  • Literature Map
  • References
  • Citations
  • Similar Papers
Abstract

Nanobodies or VHH (variable domains of heavy-chain only antibodies) are derived from camelid species such as llamas and camels. Nanobodies isolated and selected through phage display can neutralize a broad range of human immunodeficiency virus type 1 (HIV-1) strains. Nanobodies fit into canyons on the HIV envelope that may not be accessible to IgG (immunoglobulin G) containing both heavy and light chains, and they tend to have long CDR3 (complementarity-determining region 3) loops that further enhance recognition of otherwise cryptic epitopes. Nanobodies are readily expressed at high levels in bacteria and yeast, as well as by viral vectors, and they form relatively stable, heat-resistant molecules. Nanobodies can be linked to human Fc chains to gain immune effector functions. Bivalent and trivalent nanobodies recognizing the same or distinct epitopes on the envelope glycoproteins, gp120 and gp41, greatly increase the potency of HIV-1 neutralization. Nanobodies have potential applications for HIV-1 diagnostics, vaccine design, microbicides, immunoprophylaxis, and immunotherapy.

Loading PDF

Similar Papers
  • PDF
  • Research Article
  • Citations132

Microvirin, a Novel α(1,2)-Mannose-specific Lectin Isolated from Microcystis aeruginosa, Has Anti-HIV-1 Activity Comparable with That of Cyanovirin-N but a Much Higher Safety Profile

  • Aug 01, 2010
  • Journal of Biological Chemistry
  • Dana Huskens +6
  • PDF
  • Research Article
  • Citations16

Dynamics and durability of HIV-1 neutralization are determined by viral replication

  • Nov 01, 2023
  • Nature medicine
  • Philipp Schommers +49
  • PDF
  • Discussion
  • Citations12

The Cat and Mouse of HIV-1 Antibody Escape

  • Sep 18, 2009
  • PLoS Pathogens
  • John R Mascola
  • PDF
  • Supplementary Content
  • Citations10

Driving HIV-1 into a Vulnerable Corner by Taking Advantage of Viral Adaptation and Evolution

  • Mar 16, 2017
  • Frontiers in Microbiology
  • Shigeyoshi Harada +1
  • Research Article
  • Citations9

Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies

  • Nov 29, 1999
  • Vaccine
  • Geoffrey J Gorse +3
  • Research Article
  • Citations31

Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.

  • Sep 01, 1992
  • Journal of virology
  • R Q Warren +7
  • Research Article
  • Citations7

Conformation of HIV-1 Envelope Governs Rhesus CD4 Usage and Simian-Human Immunodeficiency Virus Replication.

  • Jan 11, 2022
  • mBio
  • Geraldine Vilmen +6
  • Research Article
  • Citations149

Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120.

  • Oct 08, 2008
  • Journal of virology
  • Anna Forsman +12
  • Research Article
  • Citations1

Toward an effective AIDS vaccine development

  • Dec 01, 2013
  • European Journal of Immunology
  • Keiko Sakai +1
  • Research Article
  • Citations16

Pseudotypes of vesicular stomatitis virus‐bearing envelope antigens of certain HIV‐1 strains permissively infect human syncytiotrophoblasts cultured in vitro: Implications for in vivo infection of syncytiotrophoblasts by cell‐free HIV‐1

  • Jul 13, 2001
  • Journal of Medical Virology
  • Attila Bácsi +6
  • Dissertation

Immunogenicity of a PCR-based humanized HIV envelope DNA vaccine in mice

  • Jan 01, 2003
  • Sunee Sirivichayakul
  • Research Article

Serologic evidence of exposure to Human Immunodeficiency Virus Type 1 and Dengue Virus among patients attending diagnostic Laboratory, Lagos State, Nigeria

  • Jan 26, 2022
  • Scientia Africana
  • M M Ojetunde +6
  • Research Article
  • Citations2

Enhanced in vitro human immunodeficiency virus type 1 replication in B cells expressing surface antibody to the TM Env protein.

  • Mar 01, 1994
  • Journal of virology
  • Y Tani +6
  • Research Article
  • Citations71

Mechanisms of Nonrandom Human Immunodeficiency Virus Type 1 Infection and Double Infection: Preference in Virus Entry Is Important but Is Not the Sole Factor

  • Mar 14, 2005
  • Journal of Virology
  • Jianbo Chen +6
  • Research Article
  • Citations11

Broad and potent bispecific neutralizing antibody gene delivery using adeno-associated viral vectors for passive immunization against HIV-1

  • Sep 10, 2021
  • Journal of Controlled Release
  • Shuang Li +5
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.